6-(4-Chlorophenyl)-2-propylimidazo[2,1-b][1,3,4]thiadiazole | 891384-23-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6-(4-Chlorophenyl)-2-propylimidazo[2,1-b][1,3,4]thiadiazole
• CAS: 891384-23-9
• 化学式: C₁₃H₁₂ClN₃S
• mdl: MFCD08800640
• 分子量: 277.777
• InChiKey: BMERDYPTXIMHMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  58.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(4-Chlorophenyl)-2-propylimidazo[2,1-b][1,3,4]thiadiazole 在 乙酸哌啶酯 、 三氯氧磷 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 5-{[6-(4-chlorophenyl)-2-propylimidazo[2,1-b][1,3,4]thiadiazol-5-yl]methylene}-1,3-thiazolidine-2,4-dione
  参考文献：
  名称：

  Synthesis, Hypoglycaemic, Hypolipidemic and PPARγ Agonist Activities of 5-(2-Alkyl/aryl-6-Arylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene-1,3-Thiazolidinediones

  摘要：

  A novel series of 5‐(2‐alkyl/aryl‐6‐arylimidazo[2,1‐b][1,3,4]thiadiazol‐5‐yl)methylene‐1,3‐thiazolidinediones were synthesized as possible PPARγ agonists. The structures of these target molecules were established by spectral and analytical data. All the newly synthesized compounds were screened for their in vivo hypoglycaemic and hypolipidemic activity in male Wistar rats. Further, compounds with good activity were screened for PPARγ agonist activity. Among the screened compounds, 5‐{[2‐Cyclohexyl‐6‐(4‐methoxyphenyl)imidazo[2,1‐b] [1,3,4]thiadiazol‐5‐yl]methylene}‐1,3‐thiazolidine‐2,4‐dione (3i) exhibits promising hypoglycaemic and hypolipidemic activity via potential PPARγ agonist activity.

  DOI：

  10.1111/cbdd.12140
• 作为产物：
  描述：

  5-丙基[1,3,4]噻二唑-2-胺 、 2'-溴-4-氯苯乙酮 在 sodium carbonate 作用下， 以 乙醇 为溶剂， 生成 6-(4-Chlorophenyl)-2-propylimidazo[2,1-b][1,3,4]thiadiazole
  参考文献：
  名称：

  Synthesis, Hypoglycaemic, Hypolipidemic and PPARγ Agonist Activities of 5-(2-Alkyl/aryl-6-Arylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene-1,3-Thiazolidinediones

  摘要：

  A novel series of 5‐(2‐alkyl/aryl‐6‐arylimidazo[2,1‐b][1,3,4]thiadiazol‐5‐yl)methylene‐1,3‐thiazolidinediones were synthesized as possible PPARγ agonists. The structures of these target molecules were established by spectral and analytical data. All the newly synthesized compounds were screened for their in vivo hypoglycaemic and hypolipidemic activity in male Wistar rats. Further, compounds with good activity were screened for PPARγ agonist activity. Among the screened compounds, 5‐{[2‐Cyclohexyl‐6‐(4‐methoxyphenyl)imidazo[2,1‐b] [1,3,4]thiadiazol‐5‐yl]methylene}‐1,3‐thiazolidine‐2,4‐dione (3i) exhibits promising hypoglycaemic and hypolipidemic activity via potential PPARγ agonist activity.

  DOI：

  10.1111/cbdd.12140